Abstract

Lenalidomide is a milestone in the therapeutic managementof myelodysplastic syndromes (MDS), especially in those withdel 5q abnormalities. It is currently approved by the Food andDrug Administration for the treatment of low and intermediate-1risk MDS patients with transfusion-dependent anemia associatedwith deletion 5q with or without additional chromosomal abnormalities. Lenalidomide belongs to a class of second generationimmunomodulatory drugs (IMiDs) that traces its lineage to thalidomide. However,...